Xenetic Q3 net loss $0.4M, R&D down 64% to $0.4M, cash $6.8M; advancing DNase platform toward Phase 1

Xenetic Biosciences, Inc.

2024-Q3 EPS reported -$1.89 vs consensus -$0.14 ▼ miss (-1223.5%)

Net loss of $0.4M for Q3 2024; no material revenue reported.
R&D expenses fell 63.9% YoY to $0.4M from $1.0M due to lower process development spending.
Cash and equivalents were $6.8M at September 30, 2024.
Preclinical data for DNase I combination therapies in colorectal cancer models completed; presented at SITC 2024.
Strategic focus on institutional partnerships with Tokyo Medical University and Scripps Research Institute.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.